Kristen Wolf, PA
Medical · Wichita, KSNPI 1003896689
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations.
Across 229 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$620
- Amgen$601
- AstraZeneca$448
- Johnson & Johnson$394
- Lilly USA, LLC$217
- plus $1K from 31 others
What the payments were for
- Food & beverage$4,857100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $1,118 |
| AbbVie | 33 | $620 |
| Amgen | 40 | $601 |
| AstraZeneca(2 entities) | 8 | $448 |
| Johnson & Johnson(2 entities) | 23 | $394 |
| Lilly USA, LLC | 15 | $217 |
| Bayer | 6 | $184 |
| Novartis | 9 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $94 |
| Astellas Pharma US Inc | 6 | $86 |
| Boston Scientific | 4 | $84 |
| Xeris Pharmaceuticals, Inc. | 5 | $80 |
| Merck | 5 | $79 |
| Arcutis Biotherapeutics, Inc. | 3 | $69 |
| Radius Health, Inc. | 3 | $67 |
| Sanofi | 2 | $62 |
| Kestra Medical Technology Services, Inc. | 3 | $58 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Exact Sciences | 2 | $31 |
| Galderma Laboratories, L.p. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Abiomed | 1 | $19 |
| QOL Medical, LLC | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Pfizer | 1 | $15 |
| Abbott | 1 | $15 |
| Edwards Lifesciences | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,857 in reported general payments places this provider in the 85th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 102 | $70,210 |
| OzempicSemaglutide | 31 | $31,739 |
| EliquisApixaban | 34 | $27,266 |
| JanuviaSitagliptin Phosphate | 11 | $15,431 |
| MyrbetriqMirabegron | 23 | $11,379 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $6,516 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $5,548 |
| InvokanaCanagliflozin | 11 | $5,140 |
| Atorvastatin Calcium | 454 | $2,688 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 20 | $2,230 |
| Potassium Chloride | 118 | $1,874 |
| Ezetimibe | 74 | $1,620 |
| Novolog FlexpenInsulin Aspart | 12 | $1,581 |
| Duloxetine Hcl | 71 | $1,514 |
| Levothyroxine Sodium | 225 | $1,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $448 | $70,210102 claims |
| Novo NordiskOzempic, Novolog | $1,118 | $32,80142 claims |
| PfizerEliquis | $15 | $27,26634 claims |
| MerckJanuvia | $79 | $15,43111 claims |
| Astellas Pharma US IncMyrbetriq | $86 | $11,37923 claims |
| Johnson & JohnsonInvokana | $394 | $5,14011 claims |
| AbbVieSynthroid | $620 | $1,14311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 205 medical providers in Kansas.
Other medical in Wichita
- Richard AllenbachWichita$70K
- Kathryn WelchWichita$32K
- Jason MengesWichita$15K
- Trang BrownleeWichita$11K
- Susan GeorgeWichita$10K
- Andrew OsbeckWichita$9K
- Lisa HarrisWichita$8K
- Christiane YourdonWichita$6K
- Kristen OchsnerWichita$5K
- Christine JohnsonWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.